Solu-Cortef Indications/Uses

Endocrine Disorders: Primary or secondary adrenocortical insufficiency; Acute adrenocortical insufficiency; Pre-operatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful; Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected; Congenital adrenal hyperplasia; Non-suppurative thyroiditis; Hypercalcemia associated with cancer.
Non-endocrine Disorders: Rheumatic Disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Acute and subacute bursitis; Acute gouty arthritis; Acute non-specific tenosynovitis; Ankylosing spondylitis; Epicondylitis; Post-traumatic osteoarthritis; Psoriatic arthritis; Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy); Synovitis of osteoarthritis.
Collagen Diseases: During an exacerbation or as maintenance therapy in selected cases of: Acute rheumatic carditis; Systemic dermatomyositis (polymyositis); Systemic lupus erythematosus.
Dermatologic Diseases: Bullous dermatitis herpetiformis; Exfoliative dermatitis; Mycosis fungoides; Pemphigus; Severe erythema multiforme (Stevens-Johnson syndrome); Severe psoriasis; Severe seborrheic dermatitis.
Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Acute non-infectious laryngeal edema; Atopic dermatitis; Bronchial asthma; Contact dermatitis; Drug hypersensitivity reactions; Serum sickness; Urticarial transfusion reactions.
Ophthalmic Diseases: Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Allergic conjunctivitis; Allergic corneal marginal ulcers; Anterior segment inflammation; Chorioretinitis; Diffuse posterior uveitis and choroiditis; Herpes zoster ophthalmicus; Iritis and iridocyclitis; Keratitis; Optic neuritis; Sympathetic ophthalmia.
Gastrointestinal Diseases: To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy); Regional enteritis (systemic therapy).
Respiratory Diseases: Aspiration pneumonitis; Berylliosis; Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; Loeffler's syndrome not manageable by other means; Symptomatic sarcoidosis.
Hematologic Disorders: Acquired (autoimmune) hemolytic anemia; Congenital (erythroid) hypoplastic anemia; Erythroblastopenia (RBC anemia); Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated); Secondary thrombocytopenia in adults.
Neoplastic Diseases: For palliative management of: Acute leukemia of childhood; Leukemias and lymphomas in adults.
Edematous States: To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus.
Medical Emergencies: Shock secondary to adrenocortical insufficiency or shock unresponsive to conventional therapy when adrenal cortical insufficiency may be present.
Acute allergic disorders (status asthmaticus, anaphylactic reactions, insect stings, etc.) following epinephrine.
Although there are not well controlled (double-blind, placebo) clinical trials, data from experimental animal models indicate that corticosteroids may be useful in hemorrhagic, traumatic and surgical shock in which standard therapy (e.g., fluid replacement) has not been effective (see Precautions).
Miscellaneous: Trichinosis with neurologic or myocardial involvement.
Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy.